Direct comparison
Open-Label vs. Double-Blind Trial Design
When trial blinding isn't feasible or ethical vs. when double-blinding reduces bias, and the real tradeoffs of each design choice.
Written and maintained by CASRAI Editorial Board
Last updated
Ask CASRAI · free to try
Ask about Open-Label vs. Double-Blind Trial Design
Ask your first 2 questions free below. Subscribers get 150 a day for $29 a month.
An AI assistant specialized in research administration. It cites the sources behind every answer, labels web answers and says when it can't answer.
Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.
Works on this site and inside Claude, Cursor and the AI tools you already use.
Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays free to read, with no account and no card.
How do Open-Label, Double-Blind compare side by side?
The table below compares Open-Label, Double-Blind across 6 procurement-relevant dimensions, from who knows treatment assignment through governing guidance.
Side-by-side comparison
| Dimension | Open-Label | Double-Blind |
|---|---|---|
| Who knows treatment assignment | Participant and investigator/care provider both know | Participant and outcomes assessor (often care provider too) are kept unaware |
| Typical use case | Surgical/procedural trials, some oncology trials, trials with distinguishing dosing schedules or physical product characteristics | Drug trials with subjective or assessor-dependent primary endpoints, where matched placebo or double-dummy is feasible |
| Main bias risk | Placebo/expectation effects, assessment bias, differential care/reporting/dropout between arms | Lower risk of these specific biases, though allocation concealment and other design safeguards are still needed separately |
| Design complexity/cost | Lower — no matched placebo, double-dummy, or blinded drug supply chain required | Higher — requires matched/indistinguishable product, restricted randomization-code access, unblinded pharmacist or IRT, emergency unblinding procedures |
| Best-suited endpoints | Objective, hard endpoints (mortality, validated biomarker, blinded central imaging read) | Any endpoint, but especially subjective or discretionary ones (patient-reported outcomes, clinical global impression) |
| Governing guidance | ICH E9 (bias-control principles), ICH E8(R1) (general trial design) | ICH E9 (bias-control principles), ICH E6 (blinding/masking glossary and conduct) |
Common questions
Common questions about Open-Label vs Double-Blind
Is open-label the same as unblinded?
+
Effectively yes for the participant/investigator relationship — the terms are generally used interchangeably. ClinicalTrials.gov specifically labels this masking level "None (Open Label)."
Can a trial be single-blind instead of fully open-label or fully double-blind?
+
Yes. Single-blind designs sit between the two, masking one party (commonly the participant, sometimes the assessor) while the other remains aware of assignment.
Does an open-label design automatically produce weaker evidence?
+
Not automatically — it shifts the burden onto other bias-control measures, such as objective endpoints, independent blinded adjudication, and a rigorously pre-specified analysis plan.
How does blinding status interact with non-inferiority trial design?
+
Independently — a trial's hypothesis framework (superiority vs. non-inferiority) and its blinding status are separate design axes, though they interact in practice: because non-inferiority designs are already more vulnerable to bias that pulls apparent results toward "no difference" (which can spuriously favor a claim of non-inferiority), maintaining rigorous blinding and analysis discipline matters even more in a non-inferiority context. See our Non-Inferiority vs. Superiority Trial Design comparison for the hypothesis-framework side of that decision.
Going deeper
